1. Home
  2. GKOS vs CSAN Comparison

GKOS vs CSAN Comparison

Compare GKOS & CSAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$116.08

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Logo Cosan S.A. ADS

CSAN

Cosan S.A. ADS

HOLD

Current Price

$4.05

Market Cap

5.3B

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
CSAN
Founded
1998
1936
Country
United States
Brazil
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Retail-Auto Dealers and Gas Stations
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
5.3B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
GKOS
CSAN
Price
$116.08
$4.05
Analyst Decision
Strong Buy
Buy
Analyst Count
13
3
Target Price
$125.54
$9.50
AVG Volume (30 Days)
865.8K
1.6M
Earning Date
10-29-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$469,820,000.00
$7,988,294,917.00
Revenue This Year
$31.15
$272.90
Revenue Next Year
$24.15
$0.66
P/E Ratio
N/A
N/A
Revenue Growth
30.38
2.13
52 Week Low
$73.16
$3.80
52 Week High
$163.71
$6.25

Technical Indicators

Market Signals
Indicator
GKOS
CSAN
Relative Strength Index (RSI) 76.42 31.70
Support Level $105.88 $4.62
Resistance Level $116.72 $4.90
Average True Range (ATR) 3.26 0.23
MACD 0.07 -0.11
Stochastic Oscillator 94.61 0.95

Price Performance

Historical Comparison
GKOS
CSAN

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About CSAN Cosan S.A. ADS

Cosan SA engages in several services throughout the energy and logistics sectors. Its reportable segments are Raizen, Compass, Moove, Rumo, and Radar. It generates the majority of its revenue from Raizen which operates in the production, commercialization, origination, and trading of ethanol, bioenergy, resale, and trading of electricity, renewable sources, marketing, origination, and trading of sugar and fuels, and lubricant.

Share on Social Networks: